一次情報の記録
第1/2相の中間データでNSVTおよびPVC負担の有意な減少と心機能の改善が報告されました。FDAはNSVTを加速承認のための主要代替エンドポイントとして受け入れる意向です。ピボタル試験のデザイン最終決定は2027年上半期に見込まれ、試験開始は2027年下半期の予定です。
EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generally well tolerated across 10 participants with no clinically significant complement activation U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide oper